The primary objective is to prospectively study the comparative effectiveness and comparative safety of approved therapies for RA in a Japanese cohort of patients treated by rheumatologists. This includes assessing the incidence of adverse events of special interest, in a real-world population of rheumatoid arthritis patients. Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, and current treatment practices.
Protocol Amendment History
5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2016-04-08; most recent amendment 2025-09-29.
Status change: Enrolling by Invitation → Active, Not Recruiting2025-09-29